drugset
drugset / Trial / NCT03565003

A First-in-Human Study of JAB-3068 (SHP2 Inhibitor) in Adult Patients With Advanced Solid Tumors in China

NCT03565003 ↗

Phase 1/2 Completed 126 enrolled Jacobio Pharmaceuticals Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

This is a Phase 1/2a, open-label, multi-center study of JAB-3068 in Patients with advanced solid tumors.This study has two phases: dose escalation phase and dose expansion phase.

Timeline

Start
2018-11-20
Primary completion
2023-01-31
Completion
2023-01-31

Drugs

EvaluationDrugModalityDoseRoute
Subject JAB-3068 Small molecule 25 mg Oral
Subject JAB-3068 Small molecule 100 mg Oral

Indications

esophageal cancer head and neck cancer metastatic neoplasm non-small cell lung carcinoma